# Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

> **NCT00067080** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 195 (actual)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** ICL670, deferoxamine

## Key facts

- **NCT ID:** NCT00067080
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067080, "Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00067080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*